Literature DB >> 12643199

Alternatives to immunosuppressive drugs in human islet transplantation.

Alison Anne Cotterell1, Norma Sue Kenyon.   

Abstract

Although intensive insulin therapy has resulted in improved metabolic control and decreases in the incidence of complications, the occurrence of severe hypoglycemia remains an issue, as does the continued potential for complications. Islet transplantation, a promising treatment for type I diabetes, has been shown to improve blood sugar levels and decrease or even abrogate the incidence of hypoglycemia. The lack of tissue availability and the toxic effects of immunosuppressants, however, limit the application of islet transplantation as a cure for diabetes. This article discusses possible alternatives to immunosuppressive drugs in human islet transplantations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12643199     DOI: 10.1007/s11892-002-0030-5

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  68 in total

1.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

2.  Histocompatibility of semipermeable membranes for implantable diffusion devices (bioartificial pancreas).

Authors:  U Siebers; T Zekorn; R G Bretzel; H Planck; M Renardy; P Zschocke; K Federlin
Journal:  Transplant Proc       Date:  1990-04       Impact factor: 1.066

3.  Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10.

Authors:  D Rea; C van Kooten; K E van Meijgaarden; T H Ottenhoff; C J Melief; R Offringa
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

4.  The use, in diabetic rats and monkeys, of artificial capillary units containing cultured islets of Langerhans (artificial endocrine pancreas).

Authors:  A M Sun; W Parisius; G M Healy; I Vacek; H G Macmorine
Journal:  Diabetes       Date:  1977-12       Impact factor: 9.461

5.  Enhancement of pancreatic islet allograft survival with ALS and donor bone marrow.

Authors:  P Panijayanond; A P Monaco
Journal:  Surg Forum       Date:  1974

6.  Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival.

Authors:  W P Min; R Gorczynski; X Y Huang; M Kushida; P Kim; M Obataki; J Lei; R M Suri; M S Cattral
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

7.  Outcome of subcutaneous islet transplantation improved by polymer device.

Authors:  J H Juang; S Bonner-Weir; Y Ogawa; J P Vacanti; G C Weir
Journal:  Transplantation       Date:  1996-06-15       Impact factor: 4.939

8.  Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1.

Authors:  L Qin; K D Chavin; Y Ding; J E Woodward; J P Favaro; J Lin; J S Bromberg
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

9.  CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells.

Authors:  A J Adler; D W Marsh; G S Yochum; J L Guzzo; A Nigam; W G Nelson; D M Pardoll
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

10.  The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli.

Authors:  K Inaba; S Turley; T Iyoda; F Yamaide; S Shimoyama; C Reis e Sousa; R N Germain; I Mellman; R M Steinman
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.